Iterative Scopes Named to the 2021 CB Insights Digital Health 150 — List of Most Innovative Digital Health Startups

·2-min read

CAMBRIDGE, Mass., December 14, 2021--(BUSINESS WIRE)--Iterative Scopes, a pioneer in the development of precision-based technologies for treating gastrointestinal diseases, has been named as one of CB Insights’ top 150 companies in Digital Health of 2021.

The Digital Health 150 is CB Insights’ annual ranking of the 150 most promising digital health startups in the world. Iterative Scopes was recognized in the Computer-Aided Imaging category.

"We here at Iterative Scopes are very excited to be named one of CB Insights’ Top 150 companies in Digital Health," said Jonathan Ng, MBBS, CEO and Founder of Iterative Scopes. "We are honored to join many amazing peers and mentors who are all working towards better health outcomes, and continue to be inspired to innovate gastroenterology care and research through computer vision technology and AI."

Iterative Scopes was selected from a pool of over 11,000 companies.

The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016, and includes startups at various investment stages of development, from early-stage to well-funded unicorns. Companies this year include startups working on data integration & analytics, hybrid remote / in-person care, digital therapeutics, clinical intelligence, and more.

About Iterative Scopes

Iterative Scopes is pioneering the application of precision medicine to gastroenterology with the aim of enhancing colorectal cancer screenings. The technology is also designed to help optimize clinical trials investigating treatment of inflammatory bowel disease. Its powerful, proprietary artificial intelligence and computer vision technologies have the potential to improve the accuracy and consistency of endoscopy readings. Iterative Scopes is initially applying these advances to improve polyp detection for colorectal cancer screenings and standardizing disease severity characterization for inflammatory bowel disease (IBD). Longer term, the company plans to establish more meaningful endpoints for GI diseases, which can be better predictors of therapeutic response and disease outcomes. Spun out of MIT in 2017, the company is based in Cambridge, Massachusetts.

SKOUT™ is not available for sale in the United States. 510(k) pending.

View source version on


Ariel Rapoport, Associate Director, Marketing
Iterative Scopes

Media Contact:
Michelle Linn
Bioscribe Inc.